A caninized mAb against the T-cell antigen CD52 (Tactress®) has been tested in two large, well-controlled studies in conjunction with cytotoxic chemotherapy for the treatment of canine T-cell lymphoma. The gene discussed is CD52; the disease is T-cell non-Hodgkin lymphoma.